Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biolinerx Ltd ADR (NQ: BLRX )

0.2717 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 38,264
Open 0.2717
Bid (Size) 0.2767 (49)
Ask (Size) 0.2848 (2)
Prev. Close 0.2717
Today's Range 0.2717 - 0.2717
52wk Range 0.2500 - 1.890
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Earnings Scheduled For November 25, 2024
Via Benzinga
Earnings Preview For BioLine Rx
Via Benzinga

Performance

YTD
-82.24%
-82.24%
1 Month
-37.67%
-37.67%
3 Month
-62.16%
-62.16%
6 Month
-62.21%
-62.21%
1 Year
-81.39%
-81.39%

More News

Read More
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
BLRX Stock Earnings: BioLine Rx Beats Revenue for Q2 2024
Via InvestorPlace
Earnings Preview For BioLine Rx
Via Benzinga
BioLine Rx Earnings Preview
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for BioLine Rx: Here's What You Need To Know
Via Benzinga
Why Arcadium Lithium Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
Via InvestorPlace
BLRX Stock Earnings: BioLine Rx Beats EPS for Q1 2024
Via InvestorPlace
BioLineRx Ltd. (NASDAQ: BLRX) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 26, 2024
Via Benzinga
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
Via FinancialNewsMedia
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
Via InvestorPlace
Earnings Scheduled For November 20, 2023
Via Benzinga
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
Via Talk Markets
3 Tech Stocks That Wall Street Loves More Than Nvidia
Via InvestorPlace
3 Top Penny Stocks to Make You a Millionaire in 5 Years
Via InvestorPlace
BioLineRx Touts Encouraging Data From Therapy Trial For First Line Pancreatic Cancer
Via Benzinga
Unity Software To Rally Around 60%? Here Are 10 Other Analyst Forecasts For Friday
Via Benzinga
Earnings Scheduled For August 30, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.